PROTON PUMP INHIBITORS OR HISTAMINE-2 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF RECURRENCES OF EROSIVE REFLUX ESOPHAGITIS - A COST-EFFECTIVENESS ANALYSIS
Ra. Harris et al., PROTON PUMP INHIBITORS OR HISTAMINE-2 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF RECURRENCES OF EROSIVE REFLUX ESOPHAGITIS - A COST-EFFECTIVENESS ANALYSIS, The American journal of gastroenterology, 92(12), 1997, pp. 2179-2187
Objectives: Erosive esophagitis is a recurring condition for which man
y patients require preventive therapy, If maintenance therapy must be
provided, the most cost-effective treatment strategy should be establi
shed, We evaluated the costs and benefits associated with three treatm
ent strategies: 1) maintenance therapy with a proton pump inhibitor (P
PI) strategy, 2) maintenance therapy with a high-dose histamine-2 rece
ptor antagonist (H2RA) strategy, and 3) maintenance therapy with a sta
ndard-dose H2RA, If patients experience a symptomatic recurrence on th
e H2RA strategies, they then receive PPI maintenance, Methods: We used
a cost-effectiveness model with a 1-yr time frame; data were obtained
from randomized trials of lansoprazole and ranitidine, from case seri
es, and expert opinion, Results: In most situations, the high-dose H2R
A strategy is the most costly, yet it is less effective than the PPI s
trategy. Among the remaining two options, the PPI strategy is more cos
tly and more effective than the standard-dose H2RA strategy, requiring
an additional $52-688 per recurrence prevented, depending on drug acq
uisition costs, The greater the degree to which esophagitis decreases
quality of life, the more cost effective is the PPI strategy, For exam
ple, with a $50,000 per quality-adjusted life year cost-effectiveness
threshold and a market-weighted average of drug costs, the PPI strateg
y appears cost effective for those patients who report that symptoms o
f esophagitis cause greater than a 9% decrement in quality of life, Co
nclusions: The high-dose H2RA strategy is not preferred in terms of ei
ther costs or benefits, The PPI strategy appears cost effective relati
ve to the standard-dose H2RA strategy in the following situations: whe
n patients are significantly bothered by esophagitis and in institutio
nal settings where the difference in drug costs between PPIs and H2RAs
is small.